Galectin Therapeutics, Inc. (NASDAQ:GALT) enjoyed a 103.79% run-up in share price since hitting record low of $0.84. The stock managed -30.65% fall and now stands at $1.72 as of 12/05/2017. At recent session, the prices were hovering between $1.28 and $1.78. This company shares are 306.98% off its target price of $7 and the current market capitalization stands at $66.46M. The recent change has given its price a -32.36% deficit over SMA 50 and -53.26% deficit over its 52-week high. The stock witnessed -30.36% declines, -2.27% declines and -27.73% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found GALT’s volatility during a week at 15.97% and during a month it has been found around 10.59%.Galectin Therapeutics, Inc. (GALT) Top Holders
Institutional investors currently hold around $9 million or 10.8% in GALT stock. Look at its top three institutional owners. Vanguard Group Inc owns $2.11 million in Galectin Therapeutics, Inc., which represents roughly 3.17% of the company’s market cap and approximately 23.44% of the institutional ownership. Similar statistics are true for the second largest owner, D.A. Davidson & Co., which owns 690,960 shares of the stock are valued at $1.71 million. The third largest holder is Advisor Group, Inc., which currently holds $1.29 million worth of this stock and that ownership represents nearly 1.94% of its market capitalization.
At the end of 09/30/2017 reporting period, 13 institutional holders increased their position in Galectin Therapeutics, Inc. (NASDAQ:GALT) by some 207,353 shares, 18 decreased positions by 304,233 and 24 held positions by 3,309,725. That puts total institutional holdings at 3,821,311 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 71,130 shares while 9 institutional investors sold out their entire positions totaling 215,405 shares.Galectin Therapeutics, Inc. (NASDAQ:GALT) Insider Trades
Multiple company employees have indulged in significant insider trading. Galectin Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Zucconi Theodore Daniel has acquired 1,000 shares of Galectin Therapeutics, Inc. (GALT) in trading session dated May. 23, 2017. These shares are worth $2,270 and were traded at $2.27 each. The SEC filing shows that 10X Fund, L.P. performed a sale of 44,312 shares. The 10% Owner disposed these shares by way of transaction on Apr. 20, 2016. The company’s shares were given away at $1.65 per share worth to an income of some $73,115 on account of 10X Fund, L.P..
Director, Czirr James C, sold 44,312 common shares of Galectin Therapeutics, Inc. (GALT) in the open market. In a transaction dated Apr. 20, 2016, the shares were put up for sale at an average price of $1.65, raking in a sum of $73,115. After this sale, 3,260,697 common shares of GALT are directly owned by the insider, with total stake valued at $5,608,399.
In the transaction dated Apr. 20, 2016, the great number of shares disposed came courtesy the 10% Owner; 10X Fund, L.P. disposed a total of 44,312 shares at an average price of $1.67, amounting to approximately $74,001. The insider now directly owns 3,260,697 shares worth $5,608,399.Galectin Therapeutics, Inc. (GALT) Analyst Guide
Several analysts have released their opinion on Galectin Therapeutics, Inc. (NASDAQ:GALT), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.